Lennart Minthon

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi request reprint [About mice and men. Not certain that findings in mice with Alzheimer disease can be applied in clinical reality]
    Lennart Minthon
    Kliniska vetenskaper, Malmo, Lunds universitet
    Lakartidningen 103:3916. 2006
  2. doi request reprint Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden
    Neurobiol Aging 31:357-67. 2010
  3. doi request reprint Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
    Dement Geriatr Cogn Disord 25:544-52. 2008
  4. pmc BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
    Annica Sjölander
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital, University of Gothenburg, Sweden
    Mol Neurodegener 5:37. 2010
  5. pmc Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Mol Neurodegener 5:11. 2010
  6. doi request reprint Long-term rivastigmine treatment in a routine clinical setting
    L Minthon
    Neuropsychiatric Clinic, Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Acta Neurol Scand 119:180-5. 2009
  7. doi request reprint Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies
    Fredrik Bostrom
    Department of Clinical Sciences, University Hospital MAS, Malmo, Sweden
    Dement Geriatr Cogn Disord 28:314-9. 2009
  8. pmc Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study
    Sebastian Palmqvist
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    PLoS ONE 7:e38639. 2012
  9. doi request reprint CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 33:156-63. 2012
  10. pmc Longitudinal study of CSF biomarkers in patients with Alzheimer's disease
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
    PLoS ONE 4:e6294. 2009

Detail Information

Publications81

  1. ncbi request reprint [About mice and men. Not certain that findings in mice with Alzheimer disease can be applied in clinical reality]
    Lennart Minthon
    Kliniska vetenskaper, Malmo, Lunds universitet
    Lakartidningen 103:3916. 2006
  2. doi request reprint Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden
    Neurobiol Aging 31:357-67. 2010
    ..In conclusion, the results show that CSF biomarkers are better predictors of progression to AD than plasma Abeta isoforms...
  3. doi request reprint Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
    Dement Geriatr Cogn Disord 25:544-52. 2008
    ..The aim was to identify subjects with incipient Alzheimer's disease (AD) among patients with mild cognitive impairment (MCI) using brief cognitive tests...
  4. pmc BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
    Annica Sjölander
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital, University of Gothenburg, Sweden
    Mol Neurodegener 5:37. 2010
    ..e., total-tau and phospho-tau181. Gene variants of BACE1 were neither associated with amyloid-related biomarkers, nor with markers for axonal degeneration in AD...
  5. pmc Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden
    Mol Neurodegener 5:11. 2010
    ..82 ([95% CI 0.55-1.24], P = 0.35) was obtained for a positive UCHL1 allele A carrier status. The present study thus do not support a protective effect of the UCHL1 S18Y polymorphism against AD...
  6. doi request reprint Long-term rivastigmine treatment in a routine clinical setting
    L Minthon
    Neuropsychiatric Clinic, Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Acta Neurol Scand 119:180-5. 2009
    ..The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer's disease (AD) in a routine clinical setting...
  7. doi request reprint Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies
    Fredrik Bostrom
    Department of Clinical Sciences, University Hospital MAS, Malmo, Sweden
    Dement Geriatr Cogn Disord 28:314-9. 2009
    ..05), but not among the AD patients or controls. Gender, age, MMSE score, Abeta42 concentration and phosphorylated tau, and CSF trace element concentrations did not influence survival in the obtained models...
  8. pmc Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study
    Sebastian Palmqvist
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    PLoS ONE 7:e38639. 2012
    ..In this study, we compared brief cognitive tests and cerebrospinal fluid (CSF) biomarkers in predicting conversion from mild cognitive impairment (MCI) to AD...
  9. doi request reprint CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 33:156-63. 2012
    ..The aim of this study was therefore to investigate CSF biomarkers, regional cerebral blood flow (rCBF) and cognitive performance in cognitively healthy older individuals...
  10. pmc Longitudinal study of CSF biomarkers in patients with Alzheimer's disease
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
    PLoS ONE 4:e6294. 2009
    ..However, previous studies on longitudinal changes of tau and Abeta42 in individual patients with AD and elderly controls report somewhat inconsistent results...
  11. ncbi request reprint Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden
    Dement Geriatr Cogn Disord 24:118-24. 2007
    ..To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples...
  12. ncbi request reprint Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:316-20. 2007
    ..05). In conclusion, the data provide further support for the view that amyloid precursor protein metabolism is disturbed in early sporadic AD and points to the usefulness of the Abeta42/Abeta40 ratio as a predictive biomarker for AD...
  13. doi request reprint Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, S 205 02 Malmo, Sweden
    Neurobiol Aging 31:215-23. 2010
    ..The changes precede cognitive decline and should be visible already in preclinical stages. We therefore aimed to investigate their relationship in cognitively healthy individuals...
  14. doi request reprint Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
    Arch Neurol 67:217-23. 2010
    ..Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer disease with good accuracy and are thought to precede cognitive deterioration...
  15. pmc A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Clin Interv Aging 8:329-39. 2013
    ..To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD)...
  16. pmc Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    BMC Neurol 12:134. 2012
    ..The aim of this study was to identify the socio-demographic and clinical factors that affect the functional response after 6 months of ChEI therapy...
  17. ncbi request reprint Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years
    Joakim Hertze
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    J Alzheimers Dis 21:1119-28. 2010
    ..However, the specificities and positive predictive values are still too low to be able to diagnose AD before the patients fulfill the clinical criteria...
  18. doi request reprint Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
    Kajsa Sämgård
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
    Int J Geriatr Psychiatry 25:403-10. 2010
    ....
  19. doi request reprint Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
    Peder Buchhave
    Neuropsychiatric Clinic, Skane University Hospital, Malmo, Sweden
    Arch Gen Psychiatry 69:98-106. 2012
    ..Early detection of prodromal Alzheimer disease (AD) is important because new disease-modifying therapies are most likely to be effective when initiated during the early stages of disease...
  20. ncbi request reprint Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden
    Neurobiol Aging 30:165-73. 2009
    ..In conclusion, the combination of rCBF and CSF biomarkers improves the risk assessment of progression to AD in patients with MCI...
  21. doi request reprint Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 26:203-11. 2008
    ....
  22. doi request reprint Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment
    Carina Wattmo
    Department of Clinical Sciences, Clinical Memory Research Unit, Malmo, Lund University, Sweden
    Alzheimer Dis Assoc Disord 25:63-72. 2011
    ..AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome...
  23. doi request reprint Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden Neuropsychiatric Clinic, Malmo University Hospital, Sweden
    Neurobiol Aging 31:1877-84. 2010
    ..Moreover, amyloid-induced toxicity has been shown to be dependent on TNFR-signaling. However, it is still unclear whether TNFRs are involved in the early stages of dementia...
  24. ncbi request reprint Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
    Sara Hall
    Department of Clinical Sciences, Lund University
    Arch Neurol 69:1445-52. 2012
    ..To assess the ability of 5 cerebrospinal fluid(CSF) biomarkers to differentiate between common dementia and parkinsonian disorders...
  25. doi request reprint Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia
    Victoria Larsson
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 32:227-34. 2011
    ..Conclusion: This study shows that memantine improves QOL in Lewy body dementias. We also demonstrate important QOL patterns which can be used in clinical practice...
  26. pmc Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy
    Malin Wennström
    Lund University, Department of Clinical Sciences Malmo, Molecular Memory Research Unit, The Wallenberg Laboratory at Skåne University Hospital, Malmo, Sweden
    PLoS ONE 8:e53250. 2013
    ....
  27. doi request reprint Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease
    Peder Buchhave
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden
    Neurosci Lett 450:56-9. 2009
    ..28, p<0.01) and sAPP-beta (r(s)=0.23, p<0.05) in cerebrospinal fluid. In conclusion, CD40-signalling might play a role in the pathogenesis of early AD...
  28. doi request reprint CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies
    Fredrik Bostrom
    Clinical Memory Research Unit, Department of Clinical Sciences, University Hospital MAS Malmö, Sweden
    Neurobiol Aging 30:1265-71. 2009
    ..Furthermore, determination of CSF-Mg and CSF-Ca concentration may be a valuable tool in distinguishing DLB from AD...
  29. doi request reprint Diabetes mellitus and elevated copeptin levels in middle age predict low cognitive speed after long-term follow-up
    Eva Tufvesson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 35:67-76. 2013
    ....
  30. ncbi request reprint Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia
    Henrietta M Nielsen
    Molecular Memory Research Unit, Wallenberg Laboratory, pl 2 entrance 46 S 20502, Malmo, Sweden
    Curr Alzheimer Res 9:257-66. 2012
    ..The HA profile in CSF, but not in plasma, and associations to other markers appear to be gender-dependent which should be taken into account in clinical examinations and future biomarker studies...
  31. pmc A new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values
    Douglas Hägerström
    Clinical Neurophysiology Unit, Department of Clinical Sciences, Lund University, Sweden
    Clin Physiol Funct Imaging 32:114-9. 2012
    ..In conclusion, our new automated method was able to quantify rCBF-SPECT images and create normal values in ranges as expected. Further studies are needed to assess the clinical value of this method and the normal values...
  32. ncbi request reprint Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level
    Kajsa Stubendorff
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 32:408-16. 2011
    ..Since anamnestic and retrospective information about disease duration are unreliable variables, we measured survival from a fixed cognitive level...
  33. pmc Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease
    Maria Björkqvist
    Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
    PLoS ONE 7:e29868. 2012
    ..Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is important in explorative biomarker studies...
  34. pmc CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease
    Karin Westin
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    PLoS ONE 7:e30525. 2012
    ..Moreover, CCR2-related signaling pathways might be new therapeutic targets for therapies aiming at slowing down the disease progression rate of AD...
  35. pmc Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
    Cecilia M Persson
    Department of Clinical Sciences in Malmo, Clinical Memory Research Unit, Lund University, Lund, Sweden
    BMC Neurol 9:7. 2009
    ..The objective was to identify separate cognitive domains in the standard assessment tools (MMSE, ADAS-Cog) and analyze the process of decline within domains during three years in Alzheimer's disease (AD) patients with donepezil treatment...
  36. doi request reprint Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses
    Hans Brunnström
    Department of Pathology, Institution of Clinical Sciences, Lund University, Sweden
    Alzheimers Dement 6:104-9. 2010
    ..Cerebrospinal fluid biomarkers should ideally be able to identify ongoing processes in the brain, but need to be further compared with neuropathological findings for evaluation of their diagnostic validity...
  37. pmc No diagnostic value of plasma clusterin in Alzheimer's disease
    Edina Silajdzic
    Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
    PLoS ONE 7:e50237. 2012
    ..There was a slight, but significant, increase in plasma clusterin in patients with depression compared to all other groups tested, which may warrant further investigation...
  38. pmc The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia
    Kajsa Stubendorff
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Sweden
    PLoS ONE 7:e45451. 2012
    ..The aim of this study was to investigate the frequency of the three most common features of autonomic dysfunction and analyze how it affects survival...
  39. doi request reprint Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests
    Sebastian Palmqvist
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden
    Int J Geriatr Psychiatry 24:1405-12. 2009
    ..The aim of this study was to suggest practical interpretations of the Mini-Mental State Examination (MMSE), clock drawing, and cube-copying to identify DLB and differentiate it from AD...
  40. doi request reprint The usefulness of cube copying for evaluating treatment of Alzheimer's disease
    Sebastian Palmqvist
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden
    Am J Alzheimers Dis Other Demen 23:439-46. 2008
    ..Cube copying measures visuospatial ability, which is often impaired in Alzheimer's disease (AD). Cube copying was examined as an evaluation of cholinesterase inhibitor (ChEI) treatment in AD...
  41. doi request reprint Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters
    Shorena Janelidze
    Psychoimmunology Unit, Section for Psychiatry, Department of Clinical Sciences, Lund University, Lund, Sweden
    Psychoneuroendocrinology 38:853-62. 2013
    ..These results warrant future studies on the detailed neurobiological functions of chemokines in psychiatric patients...
  42. doi request reprint Altered CSF orexin and α-synuclein levels in dementia patients
    Malin Wennström
    Molecular Memory Research Unit, The Wallenberg Laboratory, Skåne University Hospital SUS Malmö, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    J Alzheimers Dis 29:125-32. 2012
    ..Alterations in CSF orexin and α-synuclein levels may be related to gender which warrants further investigation...
  43. ncbi request reprint Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity
    Daniel Lindqvist
    Department of Clinical Sciences, Section of Psychiatry, Lund University Hospital, Lund SE 221 85, Sweden
    Biol Psychiatry 66:287-92. 2009
    ..Cytokine concentrations in cerebrospinal fluid (CSF) and their relationship to aspects of suicidality have previously not been investigated...
  44. ncbi request reprint Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease
    Fredrik Bostrom
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
    Alzheimer Dis Assoc Disord 21:150-4. 2007
    ....
  45. ncbi request reprint Soluble adhesion molecules and angiotensin-converting enzyme in dementia
    Henrietta M Nielsen
    Chronic Inflammatory and Degenerative Disease Research Unit, Department of Clinical Sciences, Lund University, 205 02 Malmo, Sweden
    Neurobiol Dis 26:27-35. 2007
    ..The observed patterns in adhesion molecules may reflect distinctions in the pathophysiological basis of their generation in dementia patients...
  46. doi request reprint C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells
    Leendert A Trouw
    Department of Laboratory Medicine, Lund University, Malmo, Sweden
    Mol Immunol 45:3649-60. 2008
    ..In conclusion, C4BP binds to dead brain cells and Abeta peptide in vitro, is present in CSF and possibly protects against excessive complement activation in AD brains...
  47. ncbi request reprint Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
    ..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
  48. ncbi request reprint Patients with Lewy body dementia use more resources than those with Alzheimer's disease
    Fredrik Bostrom
    Clinical Memory Research Unit, Deparment of Clinical Sciences Malmö, Lund University, Sweden
    Int J Geriatr Psychiatry 22:713-9. 2007
    ..The purpose of this study was to compare resource use and costs in patients with dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) and to assess determinants of costs of care in DLB...
  49. ncbi request reprint A Quick Test for Cognitive Speed: a measure of cognitive speed in dementia with Lewy bodies
    Maria Andersson
    Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Am J Alzheimers Dis Other Demen 22:313-8. 2007
    ..This may have clinical implications for treatment as well as for understanding the neuropathological properties of the disease...
  50. pmc Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals
    Gustav Torisson
    Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Simrisbanvägen 14, SE 205 02 Malmo, Sweden
    BMC Geriatr 12:47. 2012
    ..Detecting cognitive impairment in medical inpatients is important due to its association with adverse outcomes. Our aim was to study recognition of cognitive impairment and its association with mortality...
  51. pmc Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
    Erik Stomrud
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University SUS, 205 02 Malmo, Sweden
    Alzheimers Res Ther 2:20. 2010
    ....
  52. pmc A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
    Sebastian Palmqvist
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, S 205 02 Malmo, Sweden
    Alzheimers Res Ther 2:29. 2010
    ..In this study, A Quick Test of cognitive speed (AQT) was compared with the mini-mental state examination (MMSE) in the evaluation of treatment outcome in AD...
  53. doi request reprint Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment
    Carina Wattmo
    Department of Neuropsychiatry, Skane University Hospital, SE 205 02 Malmo, Sweden
    Gerontologist 51:17-27. 2011
    ....
  54. pmc Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study
    Joakim Hertze
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    BMC Neurol 14:64. 2014
    ..In this study we explored changes in the IGF-related system in patients with Alzheimer's disease (AD), including changes in IGF-II levels...
  55. pmc Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study
    Gustav Torisson
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Clin Interv Aging 8:1295-304. 2013
    ..The purpose of this study was to examine whether a multidisciplinary intervention targeting drug-related problems, cognitive impairment, and discharge miscommunication could reduce readmissions in a general hospital population...
  56. pmc Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease
    Joakim Hertze
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden Memory Clinic, Skane University Hospital, Malmo, Lund, Sweden
    Dement Geriatr Cogn Dis Extra 3:113-22. 2013
    ..This study investigates the relationship between WMLs, hyperphosphorylated tau (P-tau) in cerebrospinal fluid (CSF) and apolipoprotein E (APOE) ε4 genotype in prodromal Alzheimer's disease (AD)...
  57. pmc Predictors of long-term cognitive outcome in Alzheimer's disease
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, SE 205 02 Malmo, Sweden
    Alzheimers Res Ther 3:23. 2011
    ..The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibitors (ChEI)...
  58. pmc Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1-42-Induced Shedding of the Pericyte Proteoglycan NG2
    Nina Schultz
    From the Clinical Memory Research Unit, The Wallenberg Laboratory, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden NS, LM, MW and Department of Neuroscience, Mayo Clinic, Jacksonville, Florida HMN
    J Neuropathol Exp Neurol 73:684-92. 2014
    ....
  59. pmc Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Neuropsychiatr Dis Treat 7:565-76. 2011
    ..This study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of response and adherence to treatment...
  60. doi request reprint The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia
    Victoria Larsson
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Sweden
    Int J Geriatr Psychiatry 25:1030-8. 2010
    ..This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients...
  61. ncbi request reprint Regional cerebral blood flow in Alzheimer's disease: classification and analysis of heterogeneity
    Siegbert Warkentin
    Department of Clinical Physiology, Malmo University Hospital, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 17:207-14. 2004
    ..The identification of clearly distinguishable patterns of blood flow pathology in subgroups of patients lends further support to the notion that Alzheimer's disease is a heterogeneous disorder...
  62. ncbi request reprint Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden
    Lancet Neurol 5:228-34. 2006
    ..Here, we assess the association between CSF biomarkers and incipient Alzheimer's in patients with mild cognitive impairment (MCI)...
  63. ncbi request reprint The transcobalamin 776C > G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease
    Henrik Zetterberg
    Int Psychogeriatr 17:329-31. 2005
  64. ncbi request reprint Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study
    Bengt Winblad
    Karolinska Institutet, Alzheimer s Disease Research Center, Department of Neurotec, Division of Geriatric Medicine, Karolinska University Hospital, Huddinge, 14186 Stockholm, Sweden
    Lancet 367:1057-65. 2006
    ..Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living...
  65. ncbi request reprint Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden
    Patrik Midlöv
    Department of Clinical Pharmacology, Lund University Hospital, Sweden
    Eur J Clin Pharmacol 57:903-10. 2002
    ..To describe the drug use in epilepsy and Parkinson's patients living in nursing homes and to evaluate the impact of multi-speciality team intervention on health-related quality of life, activities of daily living (ADL) and confusion state...
  66. ncbi request reprint Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year
    Charley A Merrill
    Forest Research Institute, Jersey City, NJ, USA
    J Clin Psychiatry 67:1171-8. 2006
    ..Data through 1 year of VNS (collected from June 2000 to September 2003) are now reported...
  67. ncbi request reprint Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment
    Anja H Simonsen
    Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc, 2100 Copenhagen O, Denmark
    Arch Neurol 64:366-70. 2007
    ..To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides able to differentiate between patients with stable mild cognitive impairment (MCI) and those who will progress to Alzheimer disease (AD)...
  68. ncbi request reprint Associations between AQT processing speed and neuropsychological tests in neuropsychiatric patients
    Niels Peter Nielsen
    Department of Psychiatry, Hvidovre Hospital, Copenhagen, Denmark
    Am J Alzheimers Dis Other Demen 22:202-10. 2007
    ..The findings support that AQT dual-dimension naming evaluates cognitive speed (i.e., attention, set shifting, working memory) and can be used for first-line or complementary screening for mild or progressive cognitive impairments...
  69. ncbi request reprint Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
    Sandip Ray
    Satoris, Inc, 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA
    Nat Med 13:1359-62. 2007
    ..Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease...
  70. ncbi request reprint Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
    Malin E Andersson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Int J Mol Med 20:233-9. 2007
    ..018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis...
  71. doi request reprint Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Arch Neurol 65:1102-7. 2008
    ....
  72. ncbi request reprint The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Clin Chem 49:1195-8. 2003
  73. ncbi request reprint Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
    Annika Olsson
    Institute of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
    Exp Neurol 183:74-80. 2003
    ..Neither the levels of CSF-beta-sAPP nor CSF-Abeta(42) differed when comparing ApoE4 allele-positive with allele-negative individuals...
  74. ncbi request reprint [There is a need to reform dementia care. Resources are not used optimally--time for evidence-based care]
    Jan Marcusson
    Geriatriska kliniken, Universitetssjukhuset i Linköping
    Lakartidningen 103:1022-4, 1027-8. 2006
  75. ncbi request reprint Multiple rapid automatic naming measures of cognition: normal performance and effects of aging
    James M Jacobson
    Net Education Design, Inc, Arlington, Texas, USA
    Percept Mot Skills 98:739-53. 2004
    ..We conclude that normal performance time is dependent on the task, with letter and number stimuli eliciting most rapid responses, and that most rapid automatic naming times increase with age...
  76. ncbi request reprint Clinical utility of color-form naming in Alzheimer's disease: preliminary evidence
    Niels Peter Nielsen
    Hvidovre Hospital, Denmark
    Percept Mot Skills 99:1201-4. 2004
    ..e., 16% false negatives. These findings, while supporting AQT color-form naming as a screening test for reductions in cognitive speed associated with Alzheimer's disease, are preliminary given the relatively small sample...
  77. ncbi request reprint Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 419:18-22. 2007
    ....
  78. ncbi request reprint Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
    Annica Johansson
    Department of Clinical Neuroscience, Unit of Neurochemistry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Dement Geriatr Cogn Disord 20:367-74. 2005
    ..006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD...
  79. ncbi request reprint [There is a strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk]
    Kaj Blennow
    Institutionen för klinisk neurovetenskap, Sahlgrenska Universitetssjukhuset Mölndal, Sweden
    Lakartidningen 102:2468-70, 2472-5. 2005
    ..Focus is also set on the interesting similarities in neurochemical changes and pathogenic mechanisms between CTBI-B, acute traumatic brain injury (e.g. road traffic accidents) and Alzheimer's disease...
  80. doi request reprint Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease
    Lars Gerhardsson
    Department of Occupational and Environmental Medicine, Sahlgrenska Academy and University Hospital, Goteborg, Sweden
    Dement Geriatr Cogn Disord 25:508-15. 2008
    ..The homeostasis of essential metals such as copper, iron, selenium and zinc may be altered in the brain of subjects with Alzheimer's disease (AD)...